Non-invasive in vivo assessment of IDH1 mutational status in glioma

Myriam M. Chaumeil(University of California, San Francisco), Sabrina M. Ronen(University of California, San Francisco)

Nature Communications

September 10, 2013

10.1038/ncomms3429

Cited by 142

Related Papers

Hyperpolarized 13C MRI: Path to Clinical Translation in Oncology

|Neoplasia|2018|446

Applications of Magnetic Resonance in Model Systems: Cancer Therapeutics

|Neoplasia|2000|133

PI3K/mTOR inhibition of IDH1 mutant glioma leads to reduced 2HG production that is associated with increased survival

|Scientific Reports|2019|64

17-allyamino-17-demethoxygeldanamycin treatment results in a magnetic resonance spectroscopy-detectable elevation in choline-containing metabolites associated with increased expression of choline transporter SLC44A1 and phospholipase A2

|Breast Cancer Research|2010|31

Longitudinal evaluation of MPIO-labeled stem cell biodistribution in glioblastoma using high resolution and contrast-enhanced MR imaging at 14.1Tesla

|Neuro-Oncology|2012|20